课题基金 / 基金详情

Role of TRIP6 in Malignant Glioma Progression

Role of TRIP6 in Malignant Glioma Progression
TRIP6 在恶性胶质瘤进展中的作用
批准号:
8280629
负责人:
FANG-TSYR LIN
金额:
$6.19万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-05-15 至 2012-04-30

项目摘要

项目成果

FANG-TSYR LIN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Malignant glioma is the most common and lethal primary brain tumor. Despite the improvement of imaging technology and surgical removal of the tumors significantly reduces the mortality of malignant glioma, how to enhance the sensitivity to radiation and chemotherapy, and reduce the risk of tumor invasion and metastasis still remains a big challenge. The LIM domain-containing TRIP6 (Thyroid Hormone Receptor-Interacting Protein 6) is a focal adhesion molecule involved in cell motility and transcriptional control. Through the multidomain-mediated protein-protein interactions, TRIP6 binds to several components of focal complexes and promotes ERK activation, Rho signaling and cell migration in a c-Src-dependent manner. In addition, TRIP6 is capable of shuttling to the nucleus to serve as a coactivator of NF-?B, AP-1 and E2F1 in the transcriptional regulation of genes involved in anti-apoptosis and cell growth. In this proposal, we provide novel data showing that inhibition of TRIP6 expression reduces cell migration, enhances chemosensitivity and prolongs G1 phase of the cell cycle in glioblastoma multiforme cells, suggesting a critical role for TRIP6 in malignant glioma progression. As the levels of TRIP6 mRNA and proteins are overexpressed in glioblastoma multiforme, which is correlated to the disease progression, TRIP6 can be a novel therapeutic target for malignant glioma treatment. To investigate if TRIP6 can serve as a molecular marker in GMB progression and determine if we can target TRIP6 to enhance chemosensitivity and reduce the risk of GBM tumor invasion and metastasis, Aim1 will determine the roles of TRIP6 in chemoresistance, cell cycle progression and cell migration and investigate the underlying molecular mechanisms in malignant glioma cells. Aim 2 will study the biological roles of TRIP6 in GBM tumor proliferation, invasion and metastasis using a xenograft animal model and determine if inhibition of TRIP6 expression can enhance chemosensitivity in vivo. The understanding from this study will help to design more effective therapies for this devastatin disease. PUBLIC HEALTH RELEVANCE: The LIM domain-containing TRIP6 is overexpressed in glioblastoma multiforme and plays a critical role in glioma tumor migration, chemoresistance and proliferation. The goal of this project is to understand the molecular mechanisms in cultured glioma cells and in an animal model in order to translate this understanding into more effective therapies for this devastating disease.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.cellsig.2011.06.004
发表时间: 2011-11
期刊: Cellular signalling
影响因子: 4.8
作者: [Lin VT, Lin FT]
通讯作者: Lin FT
14-3-3tau drives estrogen receptor loss and breast cancer progression
  • 批准号:
    10655783
  • 项目类别:
  • 资助金额:
    $36.6万
  • 财政年份:
    2023
  • 负责人:
    FANG-TSYR LIN
  • 依托单位:
Novel therapeutics for targeting checkpoint dysfunction in cancer
  • 批准号:
    10553175
  • 项目类别:
  • 资助金额:
    $37.48万
  • 财政年份:
    2016
  • 负责人:
    FANG-TSYR LIN
  • 依托单位:
Novel therapeutics for targeting checkpoint dysfunction in cancer
  • 批准号:
    9232389
  • 项目类别:
  • 资助金额:
    $36.26万
  • 财政年份:
    2016
  • 负责人:
    FANG-TSYR LIN
  • 依托单位:
Novel therapeutics for targeting checkpoint dysfunction in cancer
  • 批准号:
    10444747
  • 项目类别:
  • 资助金额:
    $38.25万
  • 财政年份:
    2016
  • 负责人:
    FANG-TSYR LIN
  • 依托单位:
国内基金
海外基金
TRIP6通过调控肿瘤干细胞促进大肠癌转移的机制研究
  • 批准号:
    82103506
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    苟红艳
  • 依托单位:
TRIP6通过破坏细胞紧密连接促进大肠癌侵袭与转移的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2019
  • 负责人:
    苟红艳
  • 依托单位:
TRIP6与Hippo-YAP信号之间的交互调控在结直肠癌发生及转移中的作用
  • 批准号:
    81772541
  • 项目类别:
    面上项目
  • 资助金额:
    60.0万元
  • 批准年份:
    2017
  • 负责人:
    吴华
  • 依托单位: